Navigation Links
ImaginAb, Inc. Concludes Licensing Agreement With UCLA for Novel Radiochemistry Technology
Date:4/18/2011

LOS ANGELES, April 18, 2011 /PRNewswire/ -- ImaginAb, Inc. and the University of California, Los Angeles (UCLA) have concluded a technology licensing agreement relating to novel fluorine chemistry for the rapid and robust labeling of proteins, peptides and biomolecules for diagnostic imaging with Positron Emission Tomography (PET).

"We are pleased that ImaginAb has expanded its technology portfolio and recognized the cutting-edge work being developed by the Crump Institute," said Dr. Claire Wake, Director, at the university's Office of Intellectual Property and Industry Sponsored Research (OIP-ISR).

"UCLA is truly a world leader in technologies related to PET, from Molecular and Medical Pharmacology department chair Dr. Michael Phelps' pioneering of the field some thirty years ago to the incredible multi-disciplinary innovation occurring there today," said Dr. Christian Behrenbruch, CEO of ImaginAb. "This technology will become an important part of ImaginAb's strategy to combine the readily available and low-cost supply of F-18 from existing cyclotron networks with ImaginAb's rapid development of targeted molecular imaging agents based on antibody fragments and other small protein scaffolds."

The licensed technology originates from the UCLA's Crump Institute for Molecular Imaging through research sponsored by the U.S. Department of Energy. The agreement grants exclusivity to ImaginAb for antibodies and antibody fragments.

About ImaginAb

Founded in 2007 by UCLA faculty members Dr. Robert Reiter, Professor of Urology and Molecular Biology, Dr. Anna Wu, Professor, Molecular & Medical Pharmacology and then-faculty member Dr. Behrenbruch, ImaginAb, Inc. is a biotechnology company specializing in the development of engineered antibody fragments for diagnostic imaging and novel therapeutic applications. The company has a significant pipeline of clinical products in development oriented towards unmet needs in cancer and immunology. ImaginAb is also developing a range of pre-clinical (animal imaging) reagents for use with microPET, microSPECT and optical imaging systems, and partners on a selective basis with biopharmaceutical companies with an interest in developing companion imaging agents for therapeutic antibody products. For more information about ImaginAb, visit www.imaginab.com.

Available Topic Expert(s): For information on the listed expert(s), click appropriate link.
Anna Wu
https://profnet.prnewswire.com/Subscriber/ExpertProfile.aspx?ei=91513


'/>"/>
SOURCE ImaginAb, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. ImaginAb, Inc. and BZL Biologics, LLC Conclude Licensing Agreement for Imaging Rights to huJ591/Prostate-Specific Membrane Antigen (PSMA)
2. ImaginAb, Inc. and GE Imanet Sign Agreement to Provide Customized, Targeted PET Imaging Agents for Drug Research
3. Cephalon Concludes All Outstanding Federal and State Government Investigations into the Companys Sales and Promotional Practices
4. Energy technologies not enough to sufficiently reduce carbon emissions, NYUs Hoffert concludes
5. ArunA Biomedical Announces Exclusive Worldwide Technology Licensing Agreement to Commercialize Human Embryonic Stem Cell Derived Mesenchymal Cells
6. CEL-SCI Announces Exclusive Licensing Agreement with Teva for Cancer Drug Multikine
7. Baxter Announces Licensing Agreement for Innocolls Gentamicin Surgical Implant in the United States
8. Sigma-Aldrich and the University of Illinois Offer New Boronic Acid Surrogates to Researchers Worldwide Through Licensing Agreement
9. Debiopharm and Aurigene Sign Licensing Agreement for the Development and Commercialisation of Debio 0617, a Novel Inhibitor of an Undisclosed Oncology Pathway
10. VisualSonics and Seno Medical Instruments Sign Exclusive Opto-Accoustic Licensing Agreement for Preclinical Research
11. DSM Biologics and Crucell Announce Commercial PER.C6(R) Licensing Agreement with Gedeon Richter
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/4/2016)... ... February 04, 2016 , ... Franz Inc. , an ... technology has been recognized As “ Best in Semantic Web Technology - USA ... Corporate America, it’s our priority to showcase prominent professionals who are excelling in ...
(Date:2/3/2016)... , Feb. 3, 2016  With the ... patent cliff that is underway, therapies such as ... for a whole host of indications are in ... aid in the development and production of these ... poor quality and high costs, novel approaches and ...
(Date:2/3/2016)... ... February 03, 2016 , ... ProMIS Neurosciences is currently in ... to misfolded, propagating strains of Amyloid beta involved in Alzheimer’s disease. The Company ... , Following on from the first misfolded Amyloid beta target announced on Nov. ...
(Date:2/3/2016)... , ... February 03, 2016 , ... ... to aid in the rapid development and ongoing quality control of molecular assays ... outbreak is extremely high,” Dr. Gregory R. Chiklis, President and CEO of ZeptoMetrix, ...
Breaking Biology Technology:
(Date:1/18/2016)... , Jan. 18, 2016  Extenua Inc., ... that simplifies the use and access of ubiquitous ... go-to-market partnership with American Cyber.  ... extensive experience leading transformational C4ISR and Cyber initiatives ... integrating the latest proven technology solutions," said ...
(Date:1/13/2016)... , January 13, 2016 /PRNewswire/ ... announced the addition of the  "India ... Estimation & Forecast (2015-2020)"  report ... http://www.researchandmarkets.com/research/7h6hnn/india_biometrics ) has announced the addition ... Identification Market - Estimation & Forecast ...
(Date:1/8/2016)... and MANCHESTER, United Kingdom , Jan. 8, ... of innovative sensor-based diagnostic products, today announced the closing of ... and existing investors.  Proceeds from the financing will be used ... a hand-held device for detecting early-stage pressure ulcers. ... after receiving CE Mark approval. The device,s introduction ...
Breaking Biology News(10 mins):